Adjusting the compass: new insights into the role of angiogenesis in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Growing evidence suggests that vascular perturbation plays a critical role in the pathogenesis of Alzheimer's disease (AD). It appears to be a common feature in addition to the classic pathological hallmarks of amyloid beta (Aβ) plaques and neurofibrillary. Moreover, the accumulation of Aβ in the cerebral vasculature is closely associated with cognitive decline, and disruption of the blood-brain barrier (BBB) has been shown to coincide with the onset of cognitive impairment. Although it was originally hypothesized that the accumulation of Aβ and the subsequent disruption of the BBB were due to the impaired clearance of Aβ from the brain, a body of data now suggests an alternative hypothesis for vascular dysfunction in AD that amyloidogenesis promotes extensive neoangiogenesis leading to increased vascular permeability and subsequent hypervascularization. In this review, we discuss the role Aβ plays in angiogenesis of the neurovasculature and BBB and how it may contribute to the pathogenesis of AD. These studies suggest that interventions that directly or indirectly affect angiogenesis could have beneficial effects on amyloid and other pathways in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 3×
“molecules that may enter via the peripheral circulation [29].”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 3×
“Beyond facilitating the entry of Aβ into the brain, in vitro studies have implicated RAGE in the vascular pathogenesis of AD by mediating apoptosis in the brain and suppression of CBF [31,34].”
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 13×
“Although CBF decay is associated with normal aging, more severe CBF reductions have been detected in older individuals at a high risk of developing AD prior to the onset of Aβ accumulation and cognitive decline [4-8].”
InfluentialThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 13×
“Although CBF decay is associated with normal aging, more severe CBF reductions have been detected in older individuals at a high risk of developing AD prior to the onset of Aβ accumulation and cognitive decline [4-8].”
InfluentialRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448 · cited 2×
“duction, and degradation of the capillary basement membrane [23,30].”
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., & Small, G. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430701 · Cited by 1,328
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882 · cited 1×
“Finally, BBB dysfunction was initially identified in animal models of AD [21] and was later confirmed as a prominent, though unexplained, clinical feature of AD in patients [71].”
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 6×
“Deane and Zlokovic [35] used surface plasmon resonance analysis to show that LRP1 has a high affinity for Aβ1-40 and less affinity for β-sheet Aβ1-42.”
InfluentialCerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study
Ruitenberg, A., den Heijer, T., Bakker, S. L. M., van Swieten, J. C., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20493 · Cited by 733
The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557 · cited 2×
“hypoxia, and neurodegeneration [70].”
Kim, T., Vidal, G. S., Djurisic, M., William, C. M., Birnbaum, M. E., Garcia, K. C., Hyman, B. T., & Shatz, C. J. (2013) · Science · doi:10.1126/science.1242077 · Cited by 410 · cited 1×
“These findings imply that LilrB2 contributes to human AD neuropathology [75]; however, PirB is an alternate receptor for Nogo-B, a neurite out-”
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
Self-citationCortes-Canteli, M., Paul, J., Norris, E. H., Bronstein, R., Ahn, H. J., Zamolodchikov, D., Bhuvanendran, S., Fenz, K. M., & Strickland, S. (2010) · Neuron · doi:10.1016/j.neuron.2010.05.014 · Cited by 339
Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study
Pfeifer, L. A., White, L. R., Ross, G. W., Petrovitch, H., & Launer, L. J. (2002) · Neurology · doi:10.1212/wnl.58.11.1629 · Cited by 338 · cited 1×
“Research supporting a role for pathological angiogenesis in AD suggests that it occurs as a compensatory response to impaired CBF [47], which has been found in AD mouse models [48-50] and post-mortem studies [51].”
Paul, J., Strickland, S., & Melchor, J. P. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070304 · Cited by 319
Biron, K. E., Dickstein, D. L., Gopaul, R., & Jefferies, W. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023789 · Cited by 300 · cited 15×
“Although CBF decay is associated with normal aging, more severe CBF reductions have been detected in older individuals at a high risk of developing AD prior to the onset of Aβ accumulation and cognitive decline [4-8].”
InfluentialSelf-citationNa+-dependent Glutamate Transporters (EAAT1, EAAT2, and EAAT3) of the Blood-Brain Barrier
O'Kane, R. L., Martı́nez-López, I., DeJoseph, M. R., Viña, J. R., & Hawkins, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.31891 · Cited by 268
Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease
Meyer, E. P., Ulmann-Schuler, A., Staufenbiel, M., & Krucker, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709788105 · Cited by 260 · cited 1×
“Overall, in both young and aged mice, the morphology of the vasculature appeared more dense and showed features typical of angiogenesis [64].”
Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis
Miyazaki, K., Ohta, Y., Nagai, M., Morimoto, N., Kurata, T., Takehisa, Y., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22594 · Cited by 197 · cited 1×
“in the brain, including the rate of Aβ production and oligomerization [39-41], a disruption to these critical BBB”
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184 · cited 1×
“ory impairment, decline in cognitive ability, and eventual death [15].”
Evidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153 · cited 2×
“The release of angiogenic cytokines such as thrombin and VEGF via stimulation of inflammatory pathways in AD also contributes to angiogenesis [24].”
Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. (2013) · Science · doi:10.1126/science.1235809 · Cited by 151
Thal, D. R., Capetillo-Zarate, E., Larionov, S., Staufenbiel, M., Zurbruegg, S., & Beckmann, N. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.017 · Cited by 138
Price, A. R., Xu, G., Siemienski, Z. B., Smithson, L. A., Borchelt, D. R., Golde, T. E., & Felsenstein, K. M. (2013) · Science · doi:10.1126/science.1234089 · Cited by 138
Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J. K., Rajapaksha, T. W., Ulrich, J., Jucker, M., Holtzman, D. M., Tanzi, R. E., Vassar, R., et al. (2013) · Science · doi:10.1126/science.1235505 · Cited by 133
Tesseur, I., Lo, A. C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., Moechars, D., Mercken, M., Kemp, J., et al. (2013) · Science · doi:10.1126/science.1233937 · Cited by 128
Aβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
Dickstein, D. L., Biron, K. E., Ujiie, M., Pfeifer, C. G., Jeffries, A. R., & Jefferies, W. A. (2006) · The FASEB Journal · doi:10.1096/fj.05-3956com · Cited by 111 · cited 3×
“These findings were also supported by a later study by our laboratory which showed BBB permeability and subsequent restoration of BBB integrity with Aβ immunization in Tg2576 mice compared with non-transgenic controls in 12- and 15-month-old mice [22].”
Characteristics of Dyshoric Capillary Cerebral Amyloid Angiopathy
Richard, E., Carrano, A., Hoozemans, J. J., van Horssen, J., van Haastert, E. S., Eurelings, L. S., de Vries, H. E., Thal, D. R., Eikelenboom, P., van Gool, W. A., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181fab558 · Cited by 71 · cited 1×
“is characterized by the presence of Aβ in the pial and intracerebral small arteries and capillaries [44,45] and is associated with microaneurysms and dementia [46].”
Cited by
Vascular endothelial growth factor: a neurovascular target in neurological diseases
Lange, C., Storkebaum, E., de Almodóvar, C. R., Dewerchin, M., & Carmeliet, P. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.88 · Cited by 382
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Cerebrospinal Fluid Biomarkers of Neurovascular Dysfunction in Mild Dementia and Alzheimer'S Disease
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.76 · Cited by 122
Blood–brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy
Kozberg, M. G., Yi, I., Freeze, W. M., Auger, C. A., Scherlek, A. A., Greenberg, S. M., & van Veluw, S. J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac245 · Cited by 94
Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β
Hesse, R., Wahler, A., Gummert, P., Kirschmer, S., Otto, M., Tumani, H., Lewerenz, J., Schnack, C., & von Arnim, C. A. F. (2016) · BMC Neurology · doi:10.1186/s12883-016-0707-z · Cited by 81
Metadata
- Authors
- Jefferies, W. A., Price, K. A., Biron, K. E., Fenninger, F., Pfeifer, C. G., & Dickstein, D. L.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2013
- Volume
- 5
- Issue
- 6
- Pages
- 64
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2095613667
- Cited by
- 87
- References
- 33
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.